ENDRA Life Sciences Inc.

NDRA Healthcare Diagnostics & Research

EPS
+107.0%
Free cash flow
+15.0%

Quarter to June 2026, against a year earlier

4.74 0.27 −5.39%
Market cap
$7.5M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
5/9
Altman Z
−4.33
Beneish M
n/a
Dividend safety
n/a

ENDRA Life Sciences Inc. (NDRA) P/E ratio

Alert me on P/E ratio

ENDRA Life Sciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Mar 2018 0.0× —
Dec 2017 0.0× —
Sep 2017 0.0× —
Jun 2017 0.0× —
1 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
DMTKQ DermTech, Inc. compare n/m
MDXH MDxHealth SA compare n/m
ISPC iSpecimen Inc. compare n/m
XWEL XWELL, Inc. compare n/m
NDRA ENDRA Life Sciences Inc. n/m
BIAF bioAffinity Technologies, Inc. compare n/m
TTOO T2 Biosystems, Inc. compare n/m
AWHL Aspira Women's Health Inc. compare n/m
ADVB Advanced Biomed Inc. compare 0.3×
Diagnostics & Research industry median 34.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on NDRA